[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 296668
1. Butte JM, Torres J, O'Brien A, Jarufe N, Llanos O: [Intraductal papillary mucinous neoplasm of the pancreas]. Rev Med Chil; 2008 Apr;136(4):517-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous neoplasm of the pancreas].
  • [Transliterated title] Neoplasia mucinosa intraductal del páncreas.
  • Intraductal papillary mucinous neoplasm of the pancreas is characterized by a dilatation of the main pancreatic duct and/or secondary ducts, mucin production and the absence of ovarian-like struma.
  • The symptoms are non-specific and often the diagnosis is incidental.
  • The treatment of choice is surgery, since these tumors may become malignant.
  • The aim of this review is to analyze the clinical, diagnostic, therapeutic and pathological characteristics of this disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769796.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 38
  •  go-up   go-down


2. Murcia López A, Borrás Blasco J, Alvarado Valero MC, Navarro Ruiz A, González Delgado M, Martínez Toldos JJ: [Drug therapy for corneo-conjunctival neoplasm]. Farm Hosp; 2005 Mar;29(2):126-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug therapy for corneo-conjunctival neoplasm].
  • [Transliterated title] Tratamiento farmacológico de la neoplasia corneal y conjuntival.
  • BACKGROUND: The goal of therapy for corneo-conjunctival neoplasm is lesion removal, with the most widespread procedure being complete tumor resection with or without associated chemotherapy lines.
  • The administration of a number of topically administered drugs has been used for adjuvant therapy, including mitomycin C, 5-fluorouracil and interferon a 2b.
  • OBJECTIVE: To determine the clinical experience published regarding the effectiveness of the various drug therapies for cor-neo-conjunctival neoplasm.
  • SEARCH STRATEGY: Information reported on this topic in the Medline database (1966-2004) was searched using corneo-conjunctival neoplasm, 5-fluorouracil, mitomycin C, and interferon ca2b as key words.
  • PRIMARY RESULTS: Papers reporting the use of 5-fluorouracil re few when compared to those quoting other drugs, with a response rate of 88% and a relapse rate of 20%.
  • The use of mitomycin C is widely described in the medical literature with a response rate of 90% and a relapse rate of 13%, but in association with the development of adverse effects in a high percentage of patients.
  • Interferon ca 2b is the last drug to be incorporated in the treatment of these ocular lesions, with a response rate of 100% and a low incidence of adverse effects, with a relapse rate of 4%.
  • Interferon ct 2b has efficacy outcomes comparable to mitomycin C and a lower incidence of adverse effects, which are mostly mild in nature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Conjunctival Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16013935.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 28
  •  go-up   go-down


3. Ferrando Marco J, Pallas Regueira A, Moro Valdezate D, Fernández Martínez C: [Collision tumor of the ampulla of Vater: carcinoid and adenocarcinoma]. Rev Esp Enferm Dig; 2007 Apr;99(4):235-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Collision tumor of the ampulla of Vater: carcinoid and adenocarcinoma].
  • [Transliterated title] Tumor de colisión periampular.
  • We report the case of a periampullary collision tumor, in which a duodenal-wall carcinoid and an adenocarcinoma of the head of the pancreas coexisted.
  • A duodeno-pancreatectomy was performed, and the specimen showed two independent neoplasms in the histopathologic study.
  • Solid cords and nests of neuroendocrine cells in the duodenal wall formed the carcinoid tumor, whereas the other neoplasm was made up of a well-differentiated adenocarcinoma of the pancreas.
  • According to the literature reviewed, this is the sixth reported case of this rare neoplastic association.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Carcinoid Tumor / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590108.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Bilginer B, Söylemezoğlu F, Cila A, Akalan N: Intraventricular dysembryoplastic neuroepithelial tumor-like neoplasm with disseminated spinal tumor. Turk Neurosurg; 2009 Jan;19(1):69-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular dysembryoplastic neuroepithelial tumor-like neoplasm with disseminated spinal tumor.
  • Dysembryoplastic neuroepithelial tumor (DNT)- like lesions arise in extracortical locations and behave in a benign fashion similar to that of cortical DNTs.
  • A third ventricular mass lesion with disseminated spinal tumor was detected on his magnetic resonance imaging.
  • The presence of floating neurons in a mucinous matrix, oligodendrocyte-like cells (OLCs) aligning axonal columns and vessels, immunohistochemical profile of the neoplasm in addition to the clinical and radiological manifestations of the patient led to the diagnosis of "DNT-like neoplasm of the third ventricle".
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Magnetic Resonance Imaging. Neoplasms, Neuroepithelial / secondary. Spinal Neoplasms / secondary. Teratoma / secondary

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263357.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


5. Soto-Dávalos BA, Cortés-Flores AO, Bandera-Delgado A, Luna-Ortiz K, Padilla-Rosciano AE: [Malignant neoplasm in burn scar: Marjolin's ulcer. Report of two cases and review of the literature]. Cir Cir; 2008 Jul-Aug;76(4):329-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm in burn scar: Marjolin's ulcer. Report of two cases and review of the literature].
  • [Transliterated title] Neoplasia maligna en cicatriz de quemadura: úlcera de Marjolin. Informe de dos casos y revisión de la literatura.
  • BACKGROUND: Marjolin's ulcer forms part of a group of neoplasms that originate in a burn scar, a phenomenon associated with superficial tissue trauma.
  • For its size and as it was a high degree neoplasia, surgical resection and radiotherapy to the zone of the primary with 50 Gy in 25 fractions was decided.
  • Nonetheless, because of the aggressive behavior of this type of cancer, appropriate radical treatment allows an adequate control of the disease.
  • Early grafting of the burn site can prevent the formation a malignant neoplasm.
  • This condition should be suspected in a non-healing chronic ulcer on a burn scar.
  • [MeSH-major] Burns / complications. Carcinoma, Squamous Cell / etiology. Cicatrix / complications. Foot Diseases / etiology. Skin Neoplasms / etiology. Skin Ulcer / etiology
  • [MeSH-minor] Adult. Amputation. Back. Combined Modality Therapy. Disease Progression. Female. Foot Injuries / complications. Foot Injuries / surgery. Humans. Radiotherapy, Adjuvant. Schizophrenia, Paranoid / complications. Time Factors

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778544.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 14
  •  go-up   go-down


6. Solecki R, Kedra B, Czupryna A, Nowak K: [Solid and papillary epithelial neoplasm of the pancreas--a rare malignant tumor of pancreas]. Przegl Lek; 2005;62(12):1570-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid and papillary epithelial neoplasm of the pancreas--a rare malignant tumor of pancreas].
  • [Transliterated title] Solid and papillary epithelial neoplasm of the pancreas--rzadki guz nowotworowy trzustki.
  • The paper presents two cases of solid and papillary epithelial neoplasm of the pancreas (SPENP)--a rare pancreatic neoplasm in a 45-year-old woman admitted to the hospital with the diagnosis of pancreatic tail tumor and 22-year-old woman with the diagnosis of pancreatic head tumor.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786800.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Blasco Alfonso JE, Sales Maicas MA, Pallás Costa Y: [Paratesticular fibrosarcoma. A rare malign neoplasm]. Actas Urol Esp; 2006 Jul-Aug;30(7):707-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular fibrosarcoma. A rare malign neoplasm].
  • [Transliterated title] Fibrosarcoma paratesticular: una neoplasia maligna muy infrecuente.
  • This tumor was a fibrosarcoma in a 55 year old male that started in a most unusual way and developed very quickly.
  • [MeSH-major] Fibrosarcoma. Testicular Neoplasms

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058616.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Rerknimitr R, Ratanapanich W, Kongkam P, Kullavanijaya P: Differences in characteristics of colorectal neoplasm between young and elderly Thais. World J Gastroenterol; 2006 Dec 21;12(47):7684-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in characteristics of colorectal neoplasm between young and elderly Thais.
  • AIM: To analyze the differences of clinical characteristics of colorectal neoplasm including polyps between the elderly and young Thai patients.
  • Data were recorded on age, colonoscopic indications, tumor location, colonoscopic findings and their related histological findings.
  • No relationship was found between age and neoplasm staging and severity.
  • CONCLUSION: The chance of detecting colorectal neoplasm by colonoscopy was higher in the elderly than in the young Thais.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Jul 15;80(2):193-7 [9217029.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Mar;26(1):1-17 [9119435.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1255-9 [9752871.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Jpn J Cancer Res. 1999 Jul;90(7):705-10 [10470281.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3039-45 [10520866.001]
  • [Cites] Med Clin North Am. 2005 Jan;89(1):1-42, vii [15527807.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):47-51 [15712636.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):276-81 [16235986.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):251-8 [11227943.001]
  • [Cites] Am J Gastroenterol. 2001 Mar;96(3):882-6 [11280569.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Med Assoc Thai. 2002 Jun;85 Suppl 1:S85-90 [12188457.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1035-40 [12195187.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1400-9 [12818288.001]
  • [Cites] J Med Assoc Thai. 2003 Jun;86 Suppl 2:S459-64 [12930025.001]
  • [Cites] J Med Assoc Thai. 2004 Jan;87(1):41-6 [14971533.001]
  • [Cites] Colorectal Dis. 2004 Jul;6(4):243-9 [15206966.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):408-13 [15332032.001]
  • [Cites] BMJ. 2004 Sep 18;329(7467):665-7 [15374917.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • [Cites] Int J Cancer. 1986 Aug 15;38(2):173-6 [3733258.001]
  • [Cites] Age Ageing. 1993 Jul;22(4):260-4 [8213330.001]
  • [Cites] Surg Endosc. 1995 May;9(5):505-8 [7676371.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Nutr Rev. 1996 Sep;54(9):259-79 [9009668.001]
  • [Cites] Am J Epidemiol. 1998 Jul 1;148(1):4-16 [9663397.001]
  • (PMID = 17171800.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088053
  •  go-up   go-down


9. Carnerero Herrera V, Domínguez-Pérez A, González-Martín R, Nacarino-Mejías V, Alcázar Iribarren-Marín M: [Solitary fibrous tumor of the abdomen. A rare neoplasm of vascular origin]. Gastroenterol Hepatol; 2010 Oct;33(8):578-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of the abdomen. A rare neoplasm of vascular origin].
  • [Transliterated title] Tumor fibroso solitario abdominal. Una rara neoplasia de origen vascular.
  • Solitary fibrous tumor (formerly known as hemangiopericytoma) is a rare soft tissue neoplasm, most frequently arising from the retroperitoneum and lower extremities.
  • We present two cases of retroperitoneal solitary fibrous tumors diagnosed after surgical removal.
  • We provide a literature review showing the basic clinical, pathologic and therapeutic features of these tumors.
  • [MeSH-major] Hemangiopericytoma / pathology. Retroperitoneal Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Aged. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Fibroblasts / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Remission Induction. Tomography, X-Ray Computed. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier España, S.L. All rights reserved.
  • (PMID = 20850908.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  •  go-up   go-down


10. Aranda Flores C, Olaya Guzmán EJ, Colin Valenzuela A, Miguel Pérez PS: [Phyllodes tumor: institutional experience]. Ginecol Obstet Mex; 2009 Dec;77(12):567-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor: institutional experience].
  • [Transliterated title] Tumor phyllodes: experiencia institucional.
  • BACKGROUND: Phyllodes tumor represents one of the fibroepithelial breast neoplasms that accounts for 0.3% to 1% of the breast tumors.
  • OBJECTIVE: To describe a case series of patients with phyllodes tumor diagnosis.
  • MATERIAL AND METHODS: We retrospectively reviewed the medical records of patients that had confirmed histological phyllodes tumor collected over a period of ten years.
  • RESULTS: The incidence was 0.8%, 12.5% of cases corresponded to malignant phyllodes.
  • CONCLUSIONS: It is a rare neoplasm, andthe clinician must be aware of its timely diagnosis and treatment, if not some cases will develop breast deformity and some others will be borderline or malignant.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077881.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


11. Tomsová M, Krepinská E, Spacek J: [Sclerosing stromal tumor--a rare benign ovarian neoplasm]. Ceska Gynekol; 2008 Jun;73(3):188-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal tumor--a rare benign ovarian neoplasm].
  • [Transliterated title] Sklerozující stromální tumor--vzácný gonadostromální nádor ovaria.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of the sex cord-stromal category occurring predominantly in young women (usually younger than 30 years of age).
  • Histologically, the tumor is characterized by cellular heterogenity, prominent vascularisation, and a pseudolobular appearance composed of cellular and hypocellular areas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646673.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. Puri PK, Galan A, Glusac EJ, Cowper SE: Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm. J Cutan Pathol; 2008 Jan;35(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • OBJECTIVE: Metastatic cutaneous neoplasms may be difficult to differentiate from primary cutaneous neoplasms.
  • Herein, we report an unusual case of metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • METHODS: A 53-year-old male man presented with a neoplasm on the vertex of the scalp, clinically resembling a pigmented basal cell carcinoma.
  • After acquiring additional clinical information and the complete excision of the neoplasm, further immunohistochemical stains supported the diagnosis a metastatic carcinoid tumor.
  • CONCLUSION: To our knowledge, this is the first case of metastatic carcinoid tumor reported that has mimicked a poroid neoplasm.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Carcinoid Tumor / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095995.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Istók R, Szabó I, Illyés G: [Gastrointestinal stromal tumor metastasized to the ovary]. Orv Hetil; 2005 Jan 30;146(5):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumor metastasized to the ovary].
  • [Transliterated title] Ovariumáttétet adó gastrointestinalis stromalis tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, is originated from the interstitial cells of Cajal.
  • As a sign of malignancy, intestinal tumors particularly tend to metastasize, primarily in the abdominal cavity and in the liver.
  • The authors present a gastrointestinal stromal tumor of the intestine, which metastasized to the ovary.
  • The tumor presented as a pelvic mass, mimicking an ovarian neoplasm.
  • In the case of clinically simultaneous tumors of the gastrointestinal tract and of the ovary, one has to consider the possibility of a primary gastrointestinal tumor and first of all a gastrointestinal stromal tumor.
  • The histological diagnosis is essential because of the tumor-specific chemotherapeutical opportunity of gastrointestinal stromal tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773590.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


14. Tohma S: [Induction of malignant neoplasm]. Nihon Rinsho; 2007 Jul;65(7):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction of malignant neoplasm].
  • The induction of malignant neoplasm by biological drugs having tumor necrosis factor (TNF) inhibitory action has been concerned about, and various epidemiological studies have been done.
  • It has been shown that methotrexate could induce a malignant lymphoma in patients with rheumatoid arthritis at time.
  • With regard to malignant neoplasm induction by biological drugs, there are some reports to suggest the risk, but there are many problems about accuracy of statistics.
  • In this paper, epidemiological analyses which refer to the risk of complications or induction of malignant neoplasm by methotrexate and biological drugs in patients with rheumatoid arthritis, has been reviewed.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Arthritis, Rheumatoid / drug therapy. Immunoglobulin G / adverse effects. Methotrexate / adverse effects. Neoplasms / etiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Etanercept. Humans. Infliximab. Lymphoma / epidemiology. Lymphoma / etiology. Receptors, Tumor Necrosis Factor. Risk

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642250.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; OP401G7OJC / Etanercept; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 23
  •  go-up   go-down


15. Cibull TL, Thomas AB, O'Malley DP, Billings SD: CD4+ CD56+ hematodermic neoplasm. Am J Dermatopathol; 2007 Feb;29(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ CD56+ hematodermic neoplasm.
  • We report a case of a 75-year-old man with a cutaneous CD4+CD56+ hematodermic neoplasm.
  • CD4+CD56+ hematodermic neoplasms are rare and commonly present as cutaneous lesions.
  • [MeSH-major] Antigens, CD4 / metabolism. Antigens, CD56 / metabolism. Hematologic Neoplasms / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284963.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  •  go-up   go-down


16. Peters K, Desjardins A, Reardon DA, Perry S, Herndon JE 2nd, Bailey L, Friedman AH, Friedman HS, Bigner DD, Vredenburgh JJ: Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):e13025
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13025 Background: GBMs are vascular tumors and inherently resistant to therapy.
  • An MRI was performed after every cycle and patients continued on therapy as long as there was no tumor progression, grade 4 non-hematologic toxicity or recurrent grade 4 hematologic toxicity after a dose reduction to 150 mg/m<sup>2</sup>/d.
  • The primary endpoint was tumor response using the modified MacDonald criteria plus FLAIR and T2 sequences to evaluate non-enhancing tumor.
  • As the best response, there were 8 (25.8%) partial responses, 19 (61.3 %) patients with stable disease, and 4(12.9 %) had disease progression.
  • 19 of the 41 patients enrolled completed four cycles without tumor progression.
  • The regimen was tolerable, with 3 grade 4 hematologic toxicities including neutropenia and thrombocytopenia.
  • There were 2 grade 4 non-hematologic toxicities, including pulmonary embolism.
  • CONCLUSIONS: Upfront temozolomide and bevacizumab was well tolerated, but synergistic chemotherapy or growth factor inhibitors need to be added to produce meaningful clinical benefit, particularly for unresectable or multifocal GBM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962792.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ibrahim NK, Wong L, Rosen L, Shan J: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):1080
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1080 Background: Aminophospholipid are normally expressed on damaged or apoptotic cells, as well as on the intravascular surface of EC of vessels feeding the tumor as a result of the tumor microenvironment (e.g., hypoxia, reactive oxygen species).
  • Bavituximab (B), a novel monoclonal antibody against PS, has demonstrated preclinical anti-tumor activity by eliciting both innate and adaptive immune responses specific to tumor vasculature.
  • Here we report preliminary results of the phase I study in patients (pts) with advanced solid tumors.
  • Although not a study endpoint, tumor response was collected at day 56.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kohne C, Stroiakovski D, Chang-Chien C, Lim R, Pintér T, Bodoky G, Stroh C, Celik I, Rougier P, Van Cutsem E: Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol; 2009 May 20;27(15_suppl):4068
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous data from the phase III CRYSTAL trial showed that adding cetuximab to FOLFIRI in first-line mCRC significantly improved the overall response rate (ORR) and progression-free survival (PFS) in pts with KRAS wild-type (wt) tumors.
  • METHODS: DNA was extracted from archived tumor material where available from randomized pts.
  • In KRAS wt pts, adding cetuximab to FOLFIRI significantly increased the odds for tumor response nearly 2-fold, reduced the risk of progression by 32% and extended median OS from 21.0 months (mo) to 24.9 mo (details in Table ).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961605.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Presant CA, Bosserman L, Howard F, Emilio B: Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease. J Clin Oncol; 2009 May 20;27(15_suppl):e12004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease.
  • Although archival tissue is available in all PTs, FTT testing of molecular, immunohistochemical, and/or chemosensitivity characteristics may be more optimal for TP than tissues obtained before previous Rx and/or new mets, and archival tissue is inadequate for cell culture information.
  • In order to theoretically obtain FTT for development of a personalized TP based on an algorithm preferring in order local bx > para/thoracentesis, > non-osseous needle bx > video-assisted tissue bx > osseous bx, 18% of PTs would have had a local bx, 3% para/thoracentesis, 23% liver bx, 19% lung bx, 17% bone bx, and 12% would not have had a bx because of brain-only mets.
  • CONCLUSIONS: Most BrCa PTs in oncology practices have only locoregional disease.
  • FTT acquisition would be feasible for 88% of PTs with mets for personalized TP, and in most the bx would be simple and non-invasive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964266.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Mean length of survivors 4 year (range 4-140 month) and mean length for non-survivors 1 year (range 0.1-40 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mack PC, Holland WS, Redman M, Lara PN Jr, Snyder LJ, Hirsch FR, Franklin WA, Kim ES, Herbst RS, Gandara DR: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol; 2009 May 20;27(15_suppl):8022
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536.
  • In colorectal cancer, benefit from the EGFR-targeted monoclonal antibody cetuximab is largely limited to patients (pts) whose tumors are KRAS wild-type (WT).
  • METHODS: DNA extracted from archival tumor and plasma specimens from S0342 (carboplatin-paclitaxel plus sequential vs. concurrent cetuximab) and S0536 (carboplatin-paclitaxel-cetuximab-bevacizumab) was analyzed for KRAS mutations by micro-dissection/sequencing and/or Scorpion-ARMS (DxS LTD).
  • No differences between mutant and WT tumors were observed for response rate (p=0.62) or progression-free survival (PFS; p=0.65).
  • Overall survival (OS) was non-significantly higher for pts with WT vs. mutant KRAS [median OS: 11 vs. 8 mo. ; p=0.39].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gualberto A, Dolled-Filhart MP, Hixon ML, Christensen J, Rimm DL, Lee AV, Wang Y, Pollak M, Paz-Ares LG, Karp DD: Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):8091
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8091 Background: Signaling of Insulin like Growth Factors (IGFs) through the IGF type 1 receptor (IGF-IR) induces tumor resistance to cancer therapy.
  • Figitumumab (F) (CP-751,871), a specific IGF-IR inhibitor, has shown phase 2 activity in NSCLC in some histologies (i.e., squamous cell and adenocarcinoma) but not others (i.e, large cell or NOS tumors).
  • METHODS: Protein expression of members of the IGF-IR pathway, EGFR and differentiation markers was determined in core biopsies from 230 NSCLC pts, including 52 pts enrolled in F trials.
  • This subset included 73% of the squamous cell tumors investigated (N=44).
  • Large cell/NOS NSCLC expressed the highest levels of vimentin (p<0.001) but had low E-cadherin and IGF-IR expression and low fIGF-1 plasma levels.
  • Analysis of anchorage independent growth in NSCLC cell lines confirmed that F activity is independently associated to IGF-IR overexpression (p=0.02) and IGFBP3 under-expression (p=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Aboziada MA, El-Sayed MI, Maximous DW, Abdel-Wanis ME, Bakr MM: Feasibility of breast conservation after neoadjuvant taxae-based chemotherapy in locally advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11627
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient who had tumours ≤ 5cm underwent BC while patients who had tumour size >5cm underwent radical surgery.
  • CONCLUSIONS: Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast.
  • We recommend that patients who have tumour size ≤ 4cm after chemotherapy are the best candidates for BC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Yin W, Di G, Liu G, Wu J, Lu J, Shen K, Han Q, Shen Z, Shao Z: Demographic features and prognostic profiles of breast cancer patients presenting with nipple discharge in Chinese population. J Clin Oncol; 2009 May 20;27(15_suppl):e22204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 3234 patients, categorized as ND (2.47%) and non-nipple discharge (NND; 97.53%) according to different initial signs, were retrospectively analyzed.
  • RESULTS: ND group tended to have smaller tumors and less axillary lymph node (ALN) involvement than NND group (P < 0.05).
  • In Cox proportional hazards regression analysis, we found that tumor size (P < 0.001), ALN status (P < 0.001) were independent prognostic factors for RFS.
  • However, it was statistically significant (global test, P = 0.039), which hinted at a demand for the employment of Cox non-proportional hazards regression in this analysis.
  • In time dependent Cox model, ND status (P = 0.0495) as well as ERBB2 status (P = 0.017), tumor size (P < 0.001), ALN status (P < 0.001) were independent prognostic factors when ND and ERBB2 status were taken as time-varying covariates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964133.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Mercke C, Wickart-Johansson G, Sjödin H, Adell G, Nyman J, Haugen H: Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6040
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A brachytherapy boost of 8 Gy was given to pts with oral cavity or oropharyngeal tumours.
  • Neck dissection was planned for pts with N2-3 and complete response (CR) at the primary tumour.
  • Tumour response was evaluated according to RECIST with CT, MRI or PET/CT after CT and at 6 weeks follow up.
  • RESULTS: From 070401 to 081115 68 pts were enrolled, 56 had stage IV disease (T4, n = 14, N3, n = 9).
  • 30 pts were followed beyond 6 weeks and evaluated for response and early toxicity: stage IV disease 24 (T4, n = 6, N3, n = 3), median age 60, 25 males, 18 oropharynx, 5 larynx, and 7 hypopharynx.
  • Remissions after TPF/after RT: CR 1/10, PR 15/18, SD 14/1, and PD 1.
  • Vital tumour in resected specimen 0/13.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Petrilli AS, de Camargo B, Odone Filho V, Lustosa D, Borsato ML, Calheiros LM, Brunetto AL, Barreto JH, Ferraro AA: Fifteen years experience of the Brazilian Osteosarcoma Treatment Group (BOTG). J Clin Oncol; 2009 May 20;27(15_suppl):10039
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10039 Background: This is a 15-year analysis of disease characteristics and treatment outcome from three consecutive studies of BOTG.
  • RESULTS: Of the 604 patients, 578 were evaluable with osteosarcoma of extremities, mean age at enrollment of 14, mean time to diagnosis of 4.4 months, advanced disease (tumors diameter > 12cm) in 45% and metastatic disease in 30% of the patients.
  • Statistically significant prognostic factors were: tumor size, histological response (Huvos grade), presence of metastasis at diagnosis and type of surgery.
  • Advanced disease was associated to presence of metastasis and to a poorer histological response.
  • For non-metastatic patients, OS was 56.5% and 54% and EFS was 53% and 44%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962550.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kandioler D, Pilat N, Kappel S, Gruenberger T, Laengle F, Mittlboeck M, Herberger B, Kuehrer I, Jakesz R, Muehlbacher F: A prospective study of the interaction between p53 genotype and overall survival in patients with colorectal cancer liver metastases (CRCLM) with and without neoadjuvant therapy (oxaliplatin and capecitabine/5-FU): A p53 research group study. J Clin Oncol; 2009 May 20;27(15_suppl):e15003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15003 Background: Mutations in the p53 gene have been suggested as both a marker of tumour aggressiveness and a means of predicting response to chemotherapy.
  • METHODS: We sought to evaluate whether mutation in the p53 gene is a marker of more aggressive tumours or of chemotherapeutic failure.
  • The p53 gene was assessed in all tumours through complete direct gene sequencing (Exon 2-11 including splice sites).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964362.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Stearns V, Jacobs LK, Tsangaris TN, Briest S, Lange JR, Slater S, Fackler M, Sugar E, Gabrielson E, Davidson NE: A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14508 Background: Epigenetic modifications contribute to breast cancer initiation and progression and may be reversible, thus representing an attractive area for new drug investigation.
  • Baseline and post-treatment tumor specimens were collected for analysis of histone acetylation, candidate gene methylation and expression.
  • Median age was 55 and 80% had hormone receptor positive tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Hidalgo M, Garrido-Laguna I, Uson M, De Oliveira E, Schulick R, Hruban RH, Maitra A, Jimeno A, Rubio-Viqueira B, Rajeshkumar NV: Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development. J Clin Oncol; 2009 May 20;27(15_suppl):4528
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xenografted tumors were treated with gemcitabine and the activity in the xenograft correlated with patient clinical outcome.
  • Patients whose carcinomas engrafted had a shorter median overall survival (319 vs. 728 days, p=0.002), probably reflecting a more aggressive tumor biology in the engrafted group.
  • The response rate of gemcitabine in xenografts based on RECIST criteria was 8% (similar to response rate to gemcitabine in phase III trial by Moore et al.).
  • In the adjuvant setting, the median disease free survival (DFS) was significantly longer in those patients predicted as sensitive by the xenograft model (568 vs. 286 days, p=0.037).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962716.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. de Jong D, Dodge JE, Freedman O, Lo E, Rosen BP, Mackay H: Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS following NAC offers a survival benefit to those pts in whom optimal cytoreduction (< 1 cm residual tumor) is achieved.
  • Pts with synchronous primary tumors or final pathology inconsistent with EOC were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962464.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Buentzel J, Micke O, Glatzel M, Bruns F, Kisters K, Muecke R: Evaluation of the effect of selenium on radiation-induced toxicities in head neck cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20698
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour localizations: oral cancer 15 patients, oropharynx 19 patients, hypopharynx 5 patients, CUP 1 patient.
  • Both groups were well balanced according age, gender, localization and stage of the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961744.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Nathan PD, Vinayan A, Stott D, Goh V: CT response assessment combining reduction in size and arterial enhancement correlates with time to progression in metastatic renal cancer patients treated with TKIs. J Clin Oncol; 2009 May 20;27(15_suppl):e16062
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response assessment by RECIST criteria is insensitive as treated tumours often have only a modest change in size despite the induction of significant necrosis and does not correlate with time to progression (TTP).
  • The Choi criteria (10% size reduction or 15% contrast enhancement reduction) are routinely used in the assessment of GIST tumours treated with targeted agents.
  • Scans from 10 patients were not evaluable as non-contrast enhanced scans were performed due to impaired renal function.
  • Scans from 20 evaluable patients at baseline and 12 weeks on treatment were assessed using RECIST, Choi, and modified criteria in which both a 10% decrease in size and 15% decrease in enhancement in the arterial phase were required to define a response (PR).
  • Response assessment was performed using each of the three methods and correlated with time to disease progression (itself RECIST defined).
  • RESULTS: There was no difference in TTP between RECIST defined PR (346.8 days) and SD (328.5 days) (P=0.965).
  • TTP in Choi defined PR (358.4 days) and SD (189.6 days) groups showed improved but non-significant separation of TTP duration (P=0.266).
  • TTP in PR (421.5 days) and SD (200.3 days) groups defined by a combined assessment of reduction in size and enhancement showed greatly improved separation (P=0.064).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963066.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol; 2009 May 20;27(15_suppl):4556
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.
  • METHODS: Advanced GC tumour samples were centrally screened by immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridisation (FISH; PharmDx) in parallel.
  • Variations in tumour location and type mostly explain the difference in HER2-positivity rates between countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963029.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Terada KY, Davis J, Kitayama J, Shimizu D: Hormonal treatment of metastatic endometrial stromal sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16576
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade tumors are currently referred to as undifferentiated uterine sarcomas and are not included in this series.
  • Seven had disease confined to the uterus.
  • Six had extrauterine disease; 5 patients presented with metastases and 1 patient presented with a pelvic recurrence 20 years following a hysterectomy.
  • All 6 patients with metastases had tumors that tested positive for estrogen and progesterone receptors; all were treated with megestrol acetate initially for a period of 1-4 years.
  • Three patients with persistent disease were changed to aromatase inhibitors; 1 to letrozole and 2 to anastrazole.
  • One of these patients has had a complete response and 2 have had stable disease.
  • Follow-up for the 6 patients was 2-22 years; no known patients died of their disease.
  • CONCLUSIONS: ESS tumors are relatively uncommon and there is an absence of studies to guide treatment of patients with metastases.
  • This experience indicates that these tumors respond well to hormonal manipulation.
  • Treatment with progestins or aromatase inhibitors may result in remission or stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961495.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Awada AH Sr, Dumez H, Wolter P, Hendlisz A, Besse-Hammer T, Piccart M, Uttenreuther-Fischer M, Stopfer P, Taton M, Schöffski P: A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3556
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors.
  • : 3556 Background: BIBW 2992 (Tovok) is a potent, irreversible, new generation TKI, an inhibitor of EGFR and HER-2 (IC<sub>50</sub> 0.5 and 14 nM, respectively).
  • A Phase I dose finding study of BIBW 2992 with docetaxel is reported.
  • Four pts (breast cancer [2], thymoma [1], oesophageal carcinoma [1]) had a PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Spensley S, Gilmore JA, Kenny J, Dunne M, Clayton-Lea A, Thirion PG: Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20623
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis.
  • : e20623 Background: Malignant spinal cord compression (MSCC) is a major oncological complication.
  • The management of Impending Malignant Spinal Cord Compression (IMSCC) remains unclear.
  • Non-eligible pts were prospectively evaluated and followed with assessment of mobility (modified Tomita scale) and sphincter function (continence/ incontinence/catheter) at baseline and 5 weeks posttreatment.
  • The primary tumours were haematological [13 pts], lung [10], prostate [8], renal cell [6] and breast [5].
  • New sphincter dysfunction after RT was seen in 2 pts with IMSCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961600.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Reif M, Kröz M, Schad F, von Laue H, Feder G, Matthes H, Girke M: Classification procedure of the German version of the Cancer Fatigue Scale (CFS-D). J Clin Oncol; 2009 May 20;27(15_suppl):e20608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer related fatigue (CRF) occurs with anaemia, during and after chemo- or radiotherapy and in advanced tumour states.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Clatot F, Picquenot J, Cornic M, Hamidou H, Tennevet I, Choussy O, François A, Hong L, Laberge-Le-Couteulx S, Blot E: Prognostic value of the expression of tumor necrosis factor-alpha (TNFa) and its receptors in head and neck cancer (HNC) patients: A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e17029
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the expression of tumor necrosis factor-alpha (TNFa) and its receptors in head and neck cancer (HNC) patients: A pilot study.
  • Patients with high level of TNFa or TNFR1 expression had a worse survival (p = 0.01 and p = 0.009, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961678.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS: A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. J Clin Oncol; 2009 May 20;27(15_suppl):7003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.
  • There were no differences in patient demographics or disease characteristics between the two groups at presentation.
  • In younger AML patients a higher dose of anthracycline in induction should be considered the new standard of care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern.
  • 10 pts did not undergo surgery for various reasons including disease progression (n=7), AE unrelated to treatment (n=2), and personal decision to forgo esophagectomy (n=1).
  • CONCLUSIONS: Cetuximab and XRT results in pCR's in pts with esophageal and GEJ CA (rate of pCR 13/36), including patients with either SC or adenoCA histologies.
  • G3/4 toxicities, including dysphagia were generally uncommon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Bredel M, Renfrow J, Yadav A, Alvarez A, Lin D, Scholtens D, He X, Chandler J, Scheck A, Harsh G: Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2028
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme.
  • : 2028 Background: Glioblastoma multiforme is a complex disease that involves the deregulation of overlapping signaling pathways.
  • Constitutive activation of the transcription factor nuclear factor-κB (NF-κB) has been broadly associated with various human cancers, including glioblastomas, and their therapy resistance and may be due to cross-coupling with other oncogenic pathways, such as epidermal growth factor signaling.
  • Functional analyses uncover a bona fide tumor suppressor role for IκBα in glioblastoma cells, where it functions to constrain tumorigenic and migratory potential, and induce spontaneous cellular senescence, and apoptosis in response to treatment.
  • Glioblastomas with initially high IκBα expression significantly repress IκBα upon tumor recurrence, suggesting an acquired mechanism to evade its tumor-suppressive and/or chemo-sensitizing effects during tumor progression.
  • CONCLUSIONS: IκBα is a molecular determinant of biological tumor behavior and patient survival in glioblastoma multiforme.
  • Deletion of NFKBIA could present an alternate mechanism to activate EGFR signaling in EGFR non-amplified glioblastomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964596.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Harris TJ, Jones DR, Brenin CM, Kelly KA, George K, Moskaluk CA: Evaluation of plectin-1 immunohistochemical staining in human non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22118
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of plectin-1 immunohistochemical staining in human non-small cell lung cancer.
  • : e22118 Background: Plectin-1 (PLEC1), a known scaffolding protein, impacts signaling pathways and has been found to be up-regulated and redistributed to the cell membrane in tumor cells.
  • The purpose of this study was to examine the variation of PLEC1 staining in human non-small cell lung cancer (NSCLC).
  • A total PLEC1 immunohistochemical (IHC) staining score was obtained by multiplying the intensity of PLEC1 staining, scored 0 through 3, by the percent of tumor cells showing membrane staining, scored 1 for <25%, 2 for 25%-75% and 3 for >75%.
  • The samples were then grouped into low (0-2), intermediate (3-5) or high (6- 9) membrane expression and analyzed for clinical correlations to tumor type and pathological staging.
  • There was a trend of lower PLEC1 staining as the tumor stage advanced (p=0.1).
  • As this biomarker is being developed for molecular imaging modalities in other tumor types, it may have potential to be of use in the non-invasive detection of disease or therapeutic efficacy monitoring in NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Park SR, Lee JS, Kim YW, Choi IJ, Ryu KW, Lee JH, Lee JY, Park YL, Park SY, Park YI, Kim NK: Prognostic value of response assessed by RECIST and WHO criteria to neoadjuvant chemotherapy in locally advanced gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15647
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15647 Background: In metastatic gastric cancer, the response to chemotherapy is assessed by RECIST or WHO criteria according to the change of tumor size.
  • There are no data, however, on the usefulness of those criteria in evaluating tumor response in the setting of neoadjuvant chemotherapy.
  • The aim of this study was to evaluate the relationship between tumor response to neoadjuvant chemotherapy-as assessed by RECIST and WHO criteria-and clinical outcome in locally advanced gastric cancer (LAGC) patients.
  • LAGC was defined as stage III or IV (M0) disease based on computed tomography (CT) according to the Japanese Classification of Gastric Carcinoma.
  • RESULTS: After chemotherapy, 40 (95%) patients underwent surgery and the remaining 2 patients showed new distant metastasis on CT scan.
  • Although R0 resection rate (93% vs 64%, P = 0.03), median relapse-free survival (RFS) (43.2 vs 7.5 months, P = 0.14), and overall survival (OS) (not reached vs 27.0 months, P = 0.10) were better in responders than non-responders, they did not differ significantly in the subgroup that subsequently underwent surgery.
  • When we redefined the decrease in tumor size judged as a response by RECIST (≥60% rather than ≥30%) and WHO (≥75% rather than ≥50%) criteria, response correlated significantly with both RFS (P = 0.03) and OS (P = 0.02).
  • CONCLUSIONS: In the neoadjuvant setting, which frequently involves smaller measurable lesions than the metastatic setting, larger changes in tumor size than those specified by RECIST and WHO criteria are needed to predict postoperative outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Parker S, Berman D, Bennett KL, Alaparthy S, Tsuchihashi Z, Chasalow SD, Zhan P: Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol; 2009 May 20;27(15_suppl):3031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Humoral response to 5 tumor antigens (Ag) and a control Ag (DHFR) were examined at baseline (BL) and at Wks 4, 8-9, and 12.
  • Peripheral T-cell populations were evaluated through flow cytometry at BL, Wk 4, and Wk 12.
  • Increases from BL in humoral responses to pneumococcal (40-50/78 pts, depending on Ab) and tetanus (58/78 pts) vaccines were noted, even in pts who did not receive on-study pneumococcal (4-9 pts) or tetanus (7 pts) vaccines.
  • Maximum increase from BL of ≥ 5-fold titer (clinically meaningful threshold) in humoral response to tumor Ag MELANA (23.2% of pts), SSX2 (20.3%), NYES01 (18.8%), MAGEA4 (10.1%), and P53 (4.3%) (DHFR, 4.3%) was noted without tumor vaccines.
  • Tumor Ag response was not associated with clinical activity (complete or partial response, or stable disease ≥ 24 wks).
  • Significant increases from BL in percents of HLA-DR+ CD4+ (p = 9.3x10<sup>-7</sup>), HLA-DR+ CD8+ (p = 0.018), and ICOS+ CD4+ (p = 0.0027) effector T cells were noted.
  • Change in tumor Ag response was not associated with clinical activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Pucciarelli S, Enzo M, Agostini M, Pizzini S, Del Bianco P, Lonardi S, Friso M, Mescoli C, Urso E, Nitti D: Cell-free circulating DNA as a promising marker of colorectal cancer detection and progression. J Clin Oncol; 2009 May 20;27(15_suppl):11059
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11059 Background: Since the pathologic stage is the most powerful prognostic factor for colorectal cancer (CRC), there is a strong need of non-invasive methods for early detection.
  • It has been suggested that cfDNA (ALU repeats of 115 bp, representative of total DNA; ALU repeats of 247 DNA, representative of tumor DNA) may be associated with presence of tumor.
  • RESULTS: The median concentrations of total cfDNA (ALU115) in the plasma samples from patients with stages III-IV and stages I-II CRC, adenoma and normal controls were 52,4, 11.9; 1.9, and 1.7 ng/ml, respectively (p<.0001).
  • The corresponding figures for tumor-related cfDNA (ALU247) were 48.8, 4.7, 2.2, and 0.7 ng/ml, respectively. (p<.0001).
  • With a cut-off of 4.86 ng/ml, total DNA (ALU115) showed a sensitivity of 78.52 (95% CI 70.6-85.1) and a specificity of 86.08 (95% CI 76.4-92.8) in distinguishing patients with CRC from non-CRC [AUC: 0.860 (95% CI 0.81-0,90), p-value=.0001].
  • With a cut-off of 3.04, cfDNA tumor-related (ALU247) showed a sensitivity of 77.94 (95% CI 70.0-84.6) and a specificity of 82.28 (95% CI 72.1-90.0) in distinguishing patients with CRC from non-CRC [AUC: 0.864 (95% CI 0.81-0,91), p-value=.0001].
  • CONCLUSIONS: Both ALU115 and ALU 247 fragments of circulating cfDNA seem promising non-invasive molecular markers of detection and progression of CRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963165.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Wosnitzer M, Lee DJ, Hirsch AJ, McKiernan JM: Predictors of renal function in nephron sparing surgery for renal cell carcinoma in solitary kidneys. J Clin Oncol; 2009 May 20;27(15_suppl):e16045
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective analysis of the Columbia Urologic Oncology database found 1327 patients were treated for RCC from 1988 - 2008, of whom 38 consecutive patients underwent PN on a solitary kidney.
  • Glomerular filtration rate (GFR) was estimated with the Modification of Diet in Renal Disease (MDRD) equation.
  • Severe chronic kidney disease (CKD) and renal failure were defined as GFR of 15-30 cc/min/1.73m2 and GFR<15, respectively.
  • The mean estimated blood loss was 465cc, the mean tumor diameter was 3.9cm, and 6 (17%) of the patients had a positive surgical margin.
  • Preoperative GFR (HR=1.01, p<0.01) and the volume of kidney removed (HR=0.93, p=0.01) were associated with severe CKD and renal failure on a univariate Cox regression analysis, but were not independent predictors after adjusting for age, race, tumor stage and grade.
  • Preoperative GFR, volume removed, age, tumor stage or grade were not independent predictors of RCC recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Li R, Xie L, Li X, Liu Q, Qian X, Jiang X, Yu L, Ding Y, Liu B: Reversion of physiological drug resistance of weakly basic drugs: The discovery of a new mechanism of PEG-PCL nanoparticles. J Clin Oncol; 2009 May 20;27(15_suppl):e13528
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversion of physiological drug resistance of weakly basic drugs: The discovery of a new mechanism of PEG-PCL nanoparticles.
  • In this study, we aimed to reveal a new mechanism of PEG-PCL nanoparticles, namely the reversion of physiological drug resistance.
  • The in vivo antitumor effect of the nanoparticles was also studied in ICR mice bearing H22 tumor with different in vivo pH values.
  • RESULTS: In vitro cytotoxicity study in four tumor cell lines showed that the cytotoxicity of free Tet decreased significantly (P<0.05) when the extracellular pH decreased from 7.4 to 6.8, while the cytotoxicity of Tet-loaded nanoparticles increased or didn't change significantly.
  • As to in vivo study, the mice with in vivo tumor pH 6.8 and treated with Tet-loaded nanoparticles exhibited best tumor inhibit rate and mildest side effect, suggesting that the use of nanoparticles was more preferable than the manipulation of tumor pH by the use of basic water.
  • CONCLUSIONS: Our study clearly demonstrated that the mPEG-PCL nanoparticles could overcome the drug resistance caused by low extracellular pH and enhance drug penetration in the tumor tissue, thus increasing the antitumor efficacy of weakly basic agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961292.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Usha L, Larson ML, Kazmi N, O'Brien T, Winkelman LA, Rotmensch J: Phase II trial of imatinib mesylate (I) in combination with docetaxel (D) in the treatment of patients (pts) with recurrent or persistent epithelial ovarian carcinoma (EOC). J Clin Oncol; 2009 May 20;27(15_suppl):e16552
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I is a multi-targeted tyrosine kinase inhibitor shown in preclinical studies to decrease interstitial pressure in the tumor and facilitate influx of chemotherapeutic agents into the tumor.
  • The primary endpoint of the study was to determine a tumor response to the study combination.
  • Pts were required to have received 1 or 2 prior chemotherapeutic regimens including a platinum compound and have performance status 0-2.
  • Tumor response was evaluated by RECIST criteria after every 3 cycles of D.
  • Treatment was continued until disease progression or unacceptable toxicity.
  • Five pts were taken off the study after 1 cycle of treatment either due to serious adverse events (SAEs) or disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960815.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yardley DA, Raefsky E, Castillo R, Lahiry A, LoCicero R, Thompson D, Shastry M, Trieu V, Knauer D, Desai N: Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol; 2009 May 20;27(15_suppl):527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This multicenter phase II pilot study was designed to evaluate the feasibility, safety, and preliminary efficacy of dual VEGF and HER-2 monoclonal antibodies of bevacizumab (B) and trastuzumab (T) administered in with neoadjuvant nab-P and carboplatin (C) with SPARC tumor correlatives.
  • TREATMENT: nab-P 125 mg/m<sup>2</sup> D1, 8, 15 with C AUC 6 D1 q28 days plus T 4 mg/kg load followed by 2 mg/kg/wk and B 5 mg/kg/wk x 6 cycles followed by surgery.
  • Post surgery T and B continued for 52 wks.
  • SPARC tumor expression was measured by immunohistochemistry.
  • Median age: 52 years (29-76), ECOG PS 0-93%, median tumor size 3.2 cm, 54% ER-/PR-, 72% node positive.
  • Pathologic responses are available for 20 pts. pCR was noted in 13/20 pts (65%) and PR was noted in 7/20 pts (35%).
  • 77% of the pCR pts (10/13) and 86% of the PR pts (6/7) were positive for SPARC.
  • CONCLUSIONS: Neoadjuvant B, T with nab-P and C is feasible and highly active with a remarkable pCR of 65%.
  • SPARC tumor correlations with pathologic response data reveal a concordance between the high response rate and high incidence of SPARC positivity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Dankwah-Quansah MA, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey LE, DeAngelis L, Omuro A: Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):e13011
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13011 Background: Intracranial hemangiopericytomas are rare primary brain tumors with a tendency to metastasize.
  • Available literature is restricted to small series of patients, and little is known regarding optimal clinical management and disease course, particularly in the targeted therapy era.
  • Disease was metastatic at presentation in only one patient.
  • Stable disease was the best observed response to these agents.
  • Metastatic sites throughout disease course included lungs in 7 patients, bone in 10, liver in 3 and chest wall in 2.
  • Given the slow growth rates, the meaning of stable disease while on chemotherapy is uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Elegbede A, Andrei A, Andrei A, Holen KD: Reconsenting patients with cancer on clinical trials: Does added risk influence continued participation? J Clin Oncol; 2009 May 20;27(15_suppl):e15610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15610 Background: The general policy endorsed by multiple professional societies and cooperative groups regarding patients on cancer clinical trials states that subjects should be informed of new adverse events or significant developments during study participation and re-consented to continue on study.
  • METHODS: We surveyed 34 patients with gastrointestinal (GI) tumors all of whom were currently enrolled in a clinical trial.
  • This could be due to multiple factors, including the terminal nature of the patients' cancer, the side effects of study therapy and the patients' response to study treatment.
  • This data could produce a reasonable adverse event grade cut-off for re-consenting patients regarding new side effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962722.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Ke L, Wei H, Na L, Na L, Xin W, Qing-Xia F: Effect of N-cadherin knock-down on invasiveness of esophageal squamous cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial to mesenchymal transition, characterized by reduced E-cadherin and increased N-cadherin expression, has been recognized as a feature of aggressive tumors, but the importance of this phenotype has not been settled in esophageal squamous cell carcinoma.
  • AIM: To examine the expressions of N-cadherin and E-cadherin in 62 normal esophageal epithelium specimens, 31 adjacent atypical hyperplasia epithelium specimens and 62 esophageal squamous cell carcinoma specimens, and to investigate the roles of N-cadherin in the invasiveness of esophageal squamous cell carcinoma cell line EC9706 transfected by N-cadherin shRNA..
  • METHODS: PV immunohistochemistry was used to detect the expression pattern of N-cadherin and E-cadherin in 62 normal esophageal epithelium specimens, 31 adjacent atypical hyperplasia epithelium specimens and 62 esophageal squamous cell carcinoma specimens.
  • CONCLUSIONS: These results suggest that N-cadherin is an important factor in the invasiveness of esophageal squamous cell carcinoma and N-cadherin may serves as a potential molecular target for biotherapy of esophageal squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Senzer NN, Kaufman H, Amatruda T, Nemunaitis M, Daniels G, Glaspy J, Goldsweig H, Coffin RS, Nemunaitis J, OncoVEX Melanoma Phase II Investigator Group: Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9035
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently completed a phase II trial involving 50 advanced melanoma patients (stage IIIc and IV) with at least one injection accessible lesion, including by ultrasound.
  • METHODS: Patients received a single IT injection of 10<sup>6</sup> pfu/ml apportioned between 10 or less injectable tumors, followed 3 wks later by 24 or less sequential injections of 10<sup>8</sup> pfu/ml every 2 wks until clinically significant disease progression, or overall or injectable lesion complete response.
  • Both injected and uninjected regional and distant disease demonstrated response including clearly documented responses at uninjected visceral sites.
  • The overall response rate was 26% (8 CR, 5 PR); 10 responses have been maintained for >6 months and 2 are ongoing at <6months, the longest currently being at 35 months from first dose.
  • 93% of patients (14 of 15) with PR, CR or surgical CR remain alive.
  • Responses of distant and visceral disease provide further compelling evidence of systemic effectiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962090.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Gronwald J, Byrski T, Huzarski T, Dent R, Bielicka V, Zuziak D, Wisniowski R, Lubinski J, Narod S: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 502 Background: Neoadjuvant chemotherapy is administered to control disease, make surgical resection possible and increase the possibility of breast tissue conservation.
  • Induction of a pathological complete response (pCR) is one of the primary goals of neoadjuvant therapy in order to achieve a better disease-free and overall survival.
  • The aim of this study was to evaluate the frequency of complete pathologic response after neo-adjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation.
  • METHODS: Twenty five women with breast cancer and a BRCA1 mutation with stage I, II, and III breast cancer between December 2006 and December 2008 were entered into this study.
  • Complete pathologic response was defined as no residual invasive disease in both the breast and axilla, however ductal carcinoma in situ was allowed.
  • Thirteen patients had tumors of greater than two centimeters (52%) and seven patients had positive lymph nodes at diagnosis (28%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Ionta M, Atzori F, Murgia M, Frau B, Barca M, Coinu A, Trogu A, Eltrudis F, Minerba L, Massidda B: Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):583
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes.
  • Conversely, there is extensive preclinical work showing that TN tumors are highly sensitive to platinum agents.
  • Only a few studies compared cisplatin vs non-cisplatin containing regimens among TN or non-TN homogeneous populations.
  • The aim of this study was to evaluate the efficacy in terms of long-term outcomes of adding cisplatin to an anthracycline-based neoadjuvant regimen (cisplatin, C) compared with a standard anthracycline-based (Non-C) regimen in T4 breast cancer according to TN or non-TN status.
  • METHODS: We retrospectively analyzed 125 consecutive T4 breast cancer pts available for ER/PR and HER2 status; 98 pts (80%) were non-TN, of whom 63 treated with Non-C and 35 treated with C regimen; 27 pts (20%) were TN, of whom 10 treated with Non-C and 17 treated with C regimen.
  • RESULTS: At a median follow-up of 101 months (8-217), estimated 10-year DFS and OS in TN pts treated with C were 47% and 59% versus 10% and 30% in pts treated with Non-C.
  • In non-TN pts DFS and OS were 57% and 70% in pts treated with C versus 37% and 49% in pts treated with Non-C.
  • CONCLUSIONS: Our data suggest that both TN and non-TN pts derive a better outcomes from the add of cisplatin over a standard anthracycline-based regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ferrer A, López D, Vidal M, Tobeña M, Serrano S, Pajares I, Millastre E, Ruiz-Echarri M, Lambea J, Tres A: Evaluation of neurological symptoms in oncologic patients at the emergency department. J Clin Oncol; 2009 May 20;27(15_suppl):e20728
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of them, 61 patients (11%) consulted for a neurologic symptom: 50 of these patients (82%) were stage IV disease and 30 (49,2%) were receiving chemotherapy treatment.
  • Of the total of patients, 14 (23%) had lung cancer; 10 patients (16%) had colorectal cancer; and 8 patients (13%) had primary central nervous system tumor.
  • Tumor progression was the diagnosis made in 27 patients (44,3%), in 14 patients (23%) the diagnosis was a metabolic alteration.
  • The most frequent diagnosis made because of these symptoms is tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962018.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Popovich M, Russu V, Lex B, Tulusan AH: A retrospective analysis of treatment in triple-negative brest cancer (TNBC). J Clin Oncol; 2009 May 20;27(15_suppl):e11623
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 6/200 pts primary had stage IV disease.
  • The estimated residual tumor size in preoperative MR correlated strongly with the histopathological tumor size (Pearson Correlation r=0,81, p< 0.01).
  • Stage IV patients with viszeral disease had a median age of 69 yrs and median OS 6,3 (2-12 mts).
  • Preoperative MR is a good tool to predict the residual tumor size after PST in all TNBC pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Vashist YK, Effenberger KE, Bachmann K, Pantel K, Izbicki JR, Yekebas EF: Use of bone marrow micrometastasis to predict disease-free and overall survival in esophageal cancer: Evaluation of 304 cases. J Clin Oncol; 2009 May 20;27(15_suppl):4519
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of bone marrow micrometastasis to predict disease-free and overall survival in esophageal cancer: Evaluation of 304 cases.
  • Associations between BMM status and clinicopathological parameters as well as disease-free (DFS) and overall survival (OS) were calculated with chi-square-, log-rank test and Cox multivariate analysis.
  • Significant correlation was found between BMM and tumor size, nodal stage and recurrence (P=0.02, 0.002 and <0.0001).
  • Also tumor size and nodal stage were found to be significant predictors, whereas age and sex were not.
  • All analyses were repeated after stratification of the study group to underlying tumor type (adenocarcinoma (AC) and squamous cell carcinoma (SCC)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Chambers AJ, Murynka T, Arlette JP, Mckinnon JG: Invasive melanoma of the face: Patterns of local and regional disease in 261 patients managed at a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):e20015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive melanoma of the face: Patterns of local and regional disease in 261 patients managed at a single institution.
  • METHODS: Patients with invasive melanoma of the face managed from 1997-2008 were identified from a large population-based tumor registry and retrospectively reviewed.
  • RESULTS: 261 patients were reviewed, mean age 68 and median tumor thickness 0.87mm.
  • Of 108 patients who were eligible for SNB (with tumor thickness >1mm, Clark level ≥IV or ulceration) this was performed in only 29 (27%).
  • Regional nodal recurrence occurred in 10 (3.8%); after negative SNB in 1 (SNB failure rate 3.7%), after unsuccessful SNB in 1, following neck dissection for nodal disease at presentation in 1, and in 7 who did not undergo SNB (including 6 patients who were eligible).
  • Due to the older age of patients with facial melanoma, most deaths occurring are from unrelated conditions, and distant metastatic disease was seen in only a small percentage of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962558.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Zakrzewski JA, Geraghty L, Hamilton H, Christos P, Krich D, Mazumdar M, Polsky D, Darvishian F, Pavlick A, Osman I: Prospective analysis of predictors of survival in melanoma patients with brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):9074
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent retrospective analysis at Memorial Sloan Kettering Cancer Center (MSKCC) identified 4 clinical variables that were associated with worse post BM survival (Raizer J et al, Neuro Oncol 2008).
  • In this study, we investigated whether primary tumor features could improve the predictability of post BM survival and examined the reproducibility of the variables identified in MSKCC study.
  • Six primary tumor characteristics, 21 clinical variables, and treatments were examined.
  • After reproducing the significance of the 4 MSKCC variables in a multivariate model, ulceration of the primary tumor was also an independent predictor of post BM survival (hazard ratio [HR] = 2.75; 95% CI = 1.30, 5.83; p=0.008) whereas mitotic index ≥3/field was not (HR=1.24; 95% CI = 0.57, 2.71; p=0.59).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Frankenthaler A, Lee M, Seery V, Renzi S, Kinnaman M, Liu V, Friedman E, Atkins MB, Cutaneous Oncology Program: Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9070
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we hypothesized that concomitant immune suppression might impact the course of the disease.
  • METHODS: We examined the Beth Israel Deaconess Medical Center Cutaneous Oncology Program database for pts with immune suppression at the time of melanoma diagnosis.
  • In addition, 3 controls matched for age, gender, stage and tumor location were identified for each case and disease outcome was compared between cases and controls.
  • Compared to the database as a whole, cases were more likely to be female (84% vs 45%) and have a higher disease stage (42% stage IIIB/C vs 26%).
  • In addition, more cases appeared to have an amelanotic primary (21% vs. 5.4%) or an atypical mole syndrome (21% vs 10.2%).
  • For pts who relapsed, the cases had a shorter disease free interval (DFI) (2.1 vs 9.7 yrs) than the controls.
  • As a consequence, cases appeared more likely to have died of their disease than controls (42% vs 23%) (p=0.10).
  • CONCLUSIONS: Compared to the general melanoma population, pts with concomitant immune suppression appear more likely to be female, have an amelanotic primary or atypical mole syndrome and more advanced disease at presentation.
  • Although pts with concomitant immune suppression are equally likely to relapse compared to matched controls, those that relapse appear to have a shorter DFI and to be less likely to be salvaged, suggesting more aggressive tumor behavior in this setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Bickell N, Weidmann J, Fei K, Leventhal H: Underuse of breast cancer adjuvant treatment: Patients' knowledge, beliefs, and medical mistrust. J Clin Oncol; 2009 May 20;27(15_suppl):6521
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6521 Background: We surveyed breast cancer patients in New York City to understand why women did not receive radiotherapy (RT) following lumpectomy, chemotherapy, or hormonal therapy for hormone receptor negative or positive tumors >1 cm, respectively.
  • METHODS: 258 New York City women recently surgically treated for a new primary stage I or II breast cancer were surveyed about their experience of care, knowledge and beliefs about breast cancer and its treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964027.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Johnson ML, Rizvi NA, Ginsberg MS, Miller VA, Kris MG, Pao W, Riely GJ: A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. J Clin Oncol; 2009 May 20;27(15_suppl):8012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salirasib inhibits KRAS-dependent growth in cell lines and xenograft models.
  • The primary endpoint was rate of RECIST non-progression at 10 wks.
  • All 23 pts in Group A and 7/10 pts in Group B had KRAS mutations.
  • The RR in pts was 0/18 for Group A and 0/8 in Group B.
  • The median TTP was 1 month (mo) and 2 mo in Groups A and B, respectively.
  • The median OS was 13 mo for Group B and not reached in Group A (median follow-up 3 mo).
  • CONCLUSIONS: After 10 wks of salirasib, 28% of previously treated pts with KRAS mutations and 38% of untreated pts had stable disease.
  • The successful enrollment over 15 months of 29 pts with tumors with known KRAS mutations demonstrates that trials of a KRAS-specific genotype in lung cancer are feasible, and should be standard in future studies targeting the KRAS pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962781.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Coleman RL, Kamat A, Iyer R, Kundra V, Garcia M, Jaffe RB, Sood AK: Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5549
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5549 Background: VEGF blockade has proved to be a promising therapeutic strategy in solid tumors, including ovarian.
  • Aflibercept, a novel fusion protein consisting of the extracellular domains of VEGFR1/2 binds VEGF A, B and PlGF.
  • METHODS: Eligible patients had measurable, recurrent disease with no more than 3 prior chemotherapeutic regimens.
  • Non-hematological toxicities (Gr 3) included headache, hypertension, fatigue and ulceration.
  • Confirmed PR was observed in 2 (22%) with 1 additional near PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962505.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Agarwala SS, Thompson J, Smithers M, Ross M, Coventry B, Minor D, Scoggins C, Hersey P, Wachter E: Chemoablation of melanoma with intralesional rose bengal (PV-10). J Clin Oncol; 2009 May 20;27(15_suppl):9060
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9060 Background: Intralesional rose bengal (PV-10, a sterile 10% solution in saline) can elicit selective ablation of solid tumors and an apparent bystander response in untreated lesions.
  • In phase 1 testing in 20 subjects with AJCC Stage III (19 subjects) or IV (1 subject) melanoma, a single injection of PV-10 into 1-20 lesions led to durable objective response (OR) at 12-24 weeks in 40% of subjects (20% CR + 20% PR by modified RECIST) and locoregional disease control (CR + PR + SD) in 75% of subjects.
  • Untreated bystander lesions achieved an OR in 15% of subjects, and all subjects with an OR of their injected lesions achieved disease control of their bystander lesions.
  • After an initial treatment of 1-20 cutaneous, subcutaneous or nodal lesions, new or incompletely responsive lesions can be retreated at weeks 8, 12 or 16, with follow-up to 52 weeks.
  • An additional 1-2 lesions, including visceral lesions, remain untreated for assessment of bystander response.
  • Interim efficacy for the first 20 subjects is also comparable to that of phase 1 (15% CR + 15% PR); efficacy data for the first 40 subjects will be presented at the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962145.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Hoffman AC, Wild P, Gauler T, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Hartmann A: Correlation of multidrug-resistance gene (MDR1) expression levels and outcome to adjuvant cisplatin/MTX based chemotherapy in patients enrolled in the AUO-AB 05/95 phase III trial. J Clin Oncol; 2009 May 20;27(15_suppl):5026
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 221 formalin fixed paraffin embedded (FFPE) tumor samples from patients with locally advanced and/or lymph node-positive bladder cancer enrolled for adjuvant therapy in the AUO-AB 05/95 phase III trial (Lehmann et al, J Clin Oncol.
  • Gene expression values (relative mRNA levels) are expressed as ratios between the target gene and internal reference gene (beta-actin).
  • We included tumor stage (pT), lymph node status (pN) and the blood vessel invasion along with the measured gene expression in a stepwise multivariate Cox proportional hazards regression model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962916.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Costa FP, de Oliveira AC, Meirelles R, Machado MM, Surjan R, Chammas M, Bottger B, Morgan D, Barbault A, Pasche B: Phase II study of intrabuccally-administered amplitude-modulated electromagnetic fields in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15573
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15573 Background: Over the past few years we have identified tumor-specific frequencies for several common forms of cancer.
  • The goal of this study was to assess the tolerability and effectiveness of electromagnetic fields amplitude-modulated at tumor-specific frequencies and administered by means of an intrabuccal spoon-shaped probe in patients with advanced hepatocellular carcinoma (HCC).
  • Three daily 60 min outpatient treatments were administered until disease progression or death.
  • RESULTS: A total of 41 patients were enrolled, 17 had Child-Pugh A, 20 Child-Pugh B disease.
  • Four patients had partial response (9.8%) and sixteen had stable disease for at least 12 weeks (39.0%) according to the RECIST criteria resulting in 48.8% disease control.
  • CONCLUSIONS: In patients with advanced HCC and impaired hepatic function, treatment with amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of anti-tumor effects, which are long-lasting in some patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962384.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Shepard RC, Talluto CC, Jacob G: Phase I study results of nanomolecular liposomal annamycin in refractory ALL. J Clin Oncol; 2009 May 20;27(15_suppl):7066
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other 2 had tumor lysis syndrome and unfortunately expired.
  • Other than the tumor lysis syndromes, there was only 1 SAE definitely related to the study drug which was a grade 3 mucositis but there were also 3 other SAEs of grade 3 or 4 mucositis probably related to the study drug which comprised the MTD determination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Castellano DE, Gomez-Martin C, Cubedo Cervera R, Garcia Lopez J, Gomez-Sanz R, Gravalos C, Nuñez Sobrino J, Cortes-Funes H: Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen. J Clin Oncol; 2009 May 20;27(15_suppl):e22220
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are few examples where the endpoint is to assess the biology of the host response to the treatment of the tumor.
  • A large number of patients with pancreatic cancer present features of the cachexia syndrome and specially a marked weight loss.
  • Clinical benefit (CB) (pain, analgesic consumption, Karnofsky and weight), QLQ-C30, serum cytokines and tumor markers were evaluated pretreatment, at 4 and 8 weeks.
  • Objective responses: 0 CR, 0 PR, 31% SD and 68%PD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964084.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Maréchal R, Demetter P, Berton A, Salmon I, Van Laethem J: Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22022
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22022 Background: The chemoreceptors CXCR4, CXCR7 and the hypoxia inductible factor-1 alpha (HIF-1α) are implicated in PA growth, dissemination and angiogenesis.
  • Based on the intensity (I) and the extend (E) of staining, cases were stratified into those with high (E x I>3) or low (E x I ≤ 3) expression of CXCR4, CXCR7 and HIF-1α and results were correlated with disease-free survival (DFS) and overall survival (OS).
  • The two groups were well-matched in terms of age, sex, tumor stage (T1-T2 vs T3-T4), tumor differentiation (poor vs well-moderate), lymph node (LN) status (N0 vs N+), lymphatic and vascular embols.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Cadranel J, Beau-Faller M, Mauguen A, Lizard S, Madelaine J, Lansiaux A, Prétet J, Madroszyk A, Chouaid C, Morin F: Biological and clinical prognostic factors in patients with advanced non-small-cell cancer (NSCLC) treated by erlotinib: Preliminary results of the ERMETIC cohort. J Clin Oncol; 2009 May 20;27(15_suppl):8079
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and clinical prognostic factors in patients with advanced non-small-cell cancer (NSCLC) treated by erlotinib: Preliminary results of the ERMETIC cohort.
  • METHODS: After a preliminary phase of validation in 16 French centers, these biomarkers were studied in available tumor specimens collected from all consecutive NSCLC patients (pts) treated by erlotinib, for the first time.
  • RESULTS: 493 of the 530 enrolled pts between 02/07 and 03/08 are included in this analysis, among whom at least 357 (72%) tumor specimens were collected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962666.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Bahl G, Urbach S, Bartels U, Hodgson DC, Millar B, Parent A, Le L, Awrey S, Laperriere N: Endocrine complications in children treated for medulloblastoma or ependymoma using radiation therapy. Outcomes in the CT-planning era. J Clin Oncol; 2009 May 20;27(15_suppl):10064
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-two received highly conformal RT to the tumor bed alone (focal RT: median dose 54 Gy, range 54-59.4), 24 received low dose cranio-spinal RT (CSI: median dose 23.4 Gy) followed by a boost to the post fossa/tumor bed (median 30.6 Gy), and 24 patients received high dose CSI (median 36 Gy) followed by a boost (median 18 Gy).
  • Thirty-five children developed evidence of endocrinopathy (Growth hormone deficiency (GHD): 31, hypothyroidism (HPT): 23, precocious puberty (PP): 6, gonadotropin deficiency: 3, ACTH deficiency: 2, and diabetes insipidus: 2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962499.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Arafat W, Abdelghany A, Awad N: A clinical trial to study the effect of adding cis-retinoic acid during and after conventional treatment for pediatric neuroblastoma patient. J Clin Oncol; 2009 May 20;27(15_suppl):10057
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical trial to study the effect of adding cis-retinoic acid during and after conventional treatment for pediatric neuroblastoma patient.
  • : 10057 Background: Neuroblastoma is predominantly a tumor of early childhood, with two thirds of the cases presenting in children younger than 5 years.
  • Cis-retinoic acid has been used as maintenance therapy for treatment of advanced neuroblastoma after BMT.
  • Patients who received cis-retinoic acid had significantly better 3-year event-free survival than patients receiving no maintenance therapy.
  • The aim of this study is to evaluate the efficacy of cis-retinoic acid when used in combination with conventional chemotherapy in pediatric patient who is newly diagnosed with locally advanced neuroblastoma.
  • METHODS: Seventeen newly diagnosed children with locally advanced neuroblastoma who is candidate to receive chemotherapy were also received cis-retinoic acid starting at a dose of 160 /m<sup>2</sup> day (day 2-15 of chemotherapy) first the 3 patients, 20% dose reduction were allowed if toxicity occurred in first cohort of patient. . Patients were giving the drugs for at least 4 cycles.
  • RT-PCR analysis of several related genes was done from tumor, sample after treatment.
  • Maximum tolerated dose were 130mg/m<sup>2</sup>, response was seen as CR 30%VGR 40, PR 12%, and PD 18%.
  • TOXICITY: Hypercalcemia mucositis, rash, and elevated liver enzymes were the main dose limiting effect of cis-retinoic acid.
  • CONCLUSIONS: Cis-retinoic acid at dose 130mg/m<sup>2</sup> is a well tolerated drug with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, De Lisi V, Sgargi P, Ceci G, Ardizzoni A: Multifactorial CNS relapse susceptibility in HER2-positive breast cancer patients: First results from a population-based registry study. J Clin Oncol; 2009 May 20;27(15_suppl):1117
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The aim of this study was to evaluate incidence, survival, and risk factors of CNS metastases in the incident breast cancer population systematically collected by the Tumor Registry of Parma Province over the 4-year period, 2004-2007.
  • CONCLUSIONS: This is the first population-based registry study analyzing CNS metastases in breast cancer in relation to tumor biological features, systemic treatment, and clinical outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Disis ML, Salazar LG, Coveler A, Waisman J, Higgins D, Childs J, Bates N, Dang Y: Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. J Clin Oncol; 2009 May 20;27(15_suppl):3000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective tumor regression has been observed in 2 of the 5 treated patients.
  • One other patient has had stable disease after treatment.
  • In patients with tumor regression, the magnitude of HER2-specific T cells in the infused product was 8-fold higher than that in patients without clinical responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962053.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Sparano JA, Goldestin LJ, Childs BH, Shak S, Badve S, Baehner FL, Davidson NE, Sledge GW Jr, Gray R, North American Breast Cancer Intergroup: Genotypic characterization of phenotypically defined triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the genotypic features of TNBC compared with hormone receptor (HR)-positive disease, and also evaluated genotypic features associated with recurrence.
  • METHODS: RNA extracted from tumor samples obtained from 764 patients with stage I-III breast cancer was analyzed by RT-PCR for 371 genes.
  • All patients received adjuvant chemotherapy (plus hormonal therapy in HR-positive disease) in trial E2197; HR and HER2 expression were evaluated by immunohistochemistry (IHC) in a central lab (J Clin Oncol 26:2473-2481).
  • Cox proportional hazard models were used to identify differences in gene expression in TNBC versus HR-positive disease, and with recurrence in phenotypically defined (by IHC) TNBC (N=246) and HR-positive (N=465) disease.
  • There was increased expression of genes for which inhibitors are currently being evaluated, including AURKB and CHK1 in TNBC, and IGF1R and RhoC in HR-positive disease.
  • Although GRB7 expression was significantly lower in the TN group, increased expression of GRB7 was the only gene in the TNBC group (but not the HR-positive group) associated with increased recurrence (p=0.04), and did not correlate with nodal status, tumor size, or grade.
  • There were significant differences in gene expression between the TN and HR-positive groups, including genes for which targeted agents are currently being evaluated in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts D: A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. J Clin Oncol; 2009 May 20;27(15_suppl):CRA6509
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : CRA6509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960770.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tournigand C, Samson B, Scheithauer W, Louvet C, Andre T, Lledo G, Latreille J, Viret F, Chibaudel B, de Gramont A: mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol; 2009 May 20;27(15_suppl):4077
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, 117 pts with a disease control after 6 cy have had a 2<sup>nd</sup> randomisation (M): B alone (7.5 mg/kg q3w, n=56) or B+E 150 mg/d (n=61) until PD.
  • RESULTS: Pts characteristics were: sex: 124M/76F, median age: 62.4 years (26-80), primary tumors: colon 152, rectum 53, synchronous metastases: 150 pts, > 1 metastase site: 115, PS 0/1: 134/66, Alk. Ph.
  • For I, 92 pts in mFOLFOX-B and 93 in XELOX-B were evaluable for toxicity (tox).
  • For M, 56 pts in B and 61 pts in B+E were evaluable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Burg ME, Janssen JT, Ottevanger PB, Kerkhofs LG, Valster F, Stouthard JM, Onstenk W, Termorshuizen F, Verweij J: Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC). J Clin Oncol; 2009 May 20;27(15_suppl):5538
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 270 patients (pts) with FIGO stage II-IV, Performance status (PS) 0-2 were randomly assigned to 3 x PC3w (P 175mg/m2 with either cisplatin [Cis] 75mg/m<sup>2</sup> or carboplatin [Car] AUC 6) or 6 x PCw (P 90mg/m2 with either Cis 70mg/m<sup>2</sup> or Car AUC 4, day 1,8,15 and day 29,36,43) followed by up to 6 cycles PC3w in both arms.
  • Pts were stratified for FIGO stage, PS, tumor size and center.
  • RESULTS: 267 pts (134 TC-3w and 133 TCw) were eligible (3 pts wrong tumor type).
  • Pt characteristics were well balanced; median age 58 years, serous 62%, residual disease >1cm 66%, FIGO stage II 7%, III 64%, IV 29%.
  • Median dose-intensity for PC3w was: P 58(47-58) and Cis 25(22.5-25) mg/m<sup>2</sup>/w, Car 2(1.6-2) AUC/w, for PCw: P 60(36-60) and Cis 44.7(30-44.7) mg/m<sup>2</sup>/w and for Car 2.7(1,6-2,7) AUC/w.
  • RR after induction therapy in 176 pts with measurable disease was 72% for TC3w and 74% for TCw (p = 0.68).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962486.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Dumont SN, Aslam MI, McAuliffe JC, Yang D, Nolden LK, Oyedeji CO, Trent JC: CXCR4-CXCL12 axis: Pivotal role as a metastatic mediator in small cell sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10569
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: CXCR4 was highly expressed on 46 % of human RMS tumor samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963792.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kim HJ, Park E, Lim W, Sei J, Koh B, Son B, Ahn S: Characteristics of bone mineral density at the time of diagnosis in postmenopausal breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22187
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with higher BMD at lumbar spine were found to have low grade disease (p<0.005).
  • The patients with hormone receptor positive breast tumor showed higher BMD at lumbar spine and lower serum 25(OH)D than hormone receptor negative tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Uetake H, Shitara K, Sugihara K: Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels of human gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15669
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, gene expression level of angiogenic factors, such as vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP) and cyclooxygenase-2 (COX-2) in human gastric cancer was studies using LCM+RT-PCR methods.
  • METHODS: Gene expression level of VEGF, TP and COX-2 were separately quantified in cancer cells and in cancerous stroma of 51 gastric cancers specimen by LCM+RT-PCR methods (Danenberg Tumor Profile).
  • And a linear relationship was observed between VEGF and TP gene expression in cancerous stroma (rs=0.768, P<0.0001, Spearman).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962756.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Billan S, Nasrallah H, Abdah-Bortnyak R, Kuten A: Analysis and utility of pretreatment and posttreatment total body iodine-131 scans in patients with thyroid carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e17031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients had lung and mediastinal uptake in known sites of metastatic disease.
  • Variables found to correlate significantly with additional uptake on the post-I131 therapy total body scintigraphies were tumor size >4cm, lymph-node involvement and extracapsular extension.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Liu S, Schally AV, Xiong S, Cote R, Hawes D, Fazli L, Gleave M, Cai J, Brands F, Engel J, Pinski J: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists. J Clin Oncol; 2009 May 20;27(15_suppl):5163
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statistical analysis revealed a correlation between strong receptor expression and higher pathologic tumor stage as well as shorter overall survival.
  • All 22 samples from patients with metastatic disease demonstrated LHRH receptor expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Karvinen K, DuBose KD, Allison RR: Use of physical activity as a health tool for cancer patients and oncologists. J Clin Oncol; 2009 May 20;27(15_suppl):9634
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential predictors of physical activity promotion (i.e., age, ethnicity, number of years practicing, tumor types treated and own physical activity participation) were tested using univariate statistics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963928.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Stephenson AJ, Klein EA, Kattan MW, Han M, Partin AW, Walsh PC, Trock BJ, Wood DP, Eggener SE, Eastham JA, Scardino PT: Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):5007
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5007 Background: Nomograms that predict prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer after radical prostatectomy are the most widely used prediction tools in oncology for treatment decision making and counseling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Yamamoto D, Yoshida H, Iwase S, Odagiri H, Kitamura K: TS-1 in patients with capecitabine-resistant breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to capecitabine was defined as either progression of disease during treatment, failure to achieve regression of disease after at least four courses, or rapid recurrence after completion of therapy.
  • Ten pts (25 %) achieved a partial response, 12 patients (30 %) patients had stable disease, and 18 (45 %) progressive disease.
  • The median time to disease progression was 26.6 weeks.
  • 7 pts experienced serious TS-1- related gastrointestinal disorder requiring dose modifications in 3 pts and treatment discontinuation in 4 pt.
  • Further, interestingly, 6 of the 40 patients (15.0%) who received TS-1 did hand-foot syndrome (HFS), although 20 of the 40 patients (50.0%) who had received capecitabine, developed HFS.
  • CONCLUSIONS: This study confirms that TS-1 achieves a high tumor control rate in pretreated MBC pts and is active in patients with capecitabine-resistant breast cancer.
  • TS-1 should be considered the reference treatment in this setting based on consistently high efficacy and good tolerability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962169.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Roth AD, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 1,564 formalin fixed paraffin embedded tissue blocks were prospectively collected and DNA from normal and tumor tissue was extracted after macrodissection.
  • Multivariate analysis including markers, T stage, N stage (for SIII), Tu grade, age <60, sex, treatment arm, and Tu site found T stage (p=0.0001) and MSI (p=0.02) as independently significant clinical predictors in SII; N stage (p<0.0001), T stage (p<0.0001), SMAD4 (p<0.0001) and P53 (p=0.01) in SIII.
  • The possibility that the stages represent different diseases, rather than sequential steps in the evolution of a single disease, needs to be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961825.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Basar AA, Whittome J: CPORT: Effective partnership working to optimize chemotherapy capacity in the UK. J Clin Oncol; 2009 May 20;27(15_suppl):e20687
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: CPORT stands for "Chemotherapy-Planning Oncology Resource Tool".
  • CONCLUSIONS: This model represents a successful new form of partnership working between the NHS and the industry to increase capacity within chemotherapy services.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Netikova I, Sedlackova E, Konopasek B, Petruzelka L: Therapy of palmar-plantar erythrodysesthesia after continual fluoropyrimidin administration with 10% uridin ointment. J Clin Oncol; 2009 May 20;27(15_suppl):e20690
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many countries, including the Czech Republic, uridin is not registered for routine medical treatment.
  • Number of chemotherapy cycles, a grade of HFS and it´s site, time of uridin local administration and a grade of HFS after treatment, were evaluted.
  • The reason was a change of therapy after tumor progresion or change of hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Ghai V, Harvey HA, Abbi KK, Barochia A, Bhardwaj C, Demers LM: Significance of CA 27.29 (MUC 1 glycoprotein) levels in patients with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We wanted to assess the significance of measuring the tumor marker (CA 27.29 levels) to monitor the clinical progress of breast cancer.
  • Patient CA 27.29 levels were correlated with clinical progression of the disease (diagnostic imaging and history and physical examinations).
  • RESULTS: Out of 330 patients with Stage I, II, and III after treatment with adjuvant therapy, 316 had no evidence of disease (NED) and had normal levels(<38) of CA 27.29.
  • Out of the14 patients with clinical evidence of disease recurrence, 3 had persistently elevated levels.
  • Of the 62 patients with stage IV breast cancer following cheomotherapy, 29 patients had clinical progression of disease with 20 (69%) patients showing increasing levels.
  • Out of the 33 patients with no evidence of progression of disease only 4(12%) had increasing levels.
  • However, increasing levels of CA27.29 in metastatic disease correlate well with clinical progression of the disease.
  • A large multicenter prospective study is warranted to further assess the role of CA 27.29 for disease monitoring in locally advanced and metastatic breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Darling G, Maziak D, Inculet R, Gulenchyn K, Driedger A, Ung Y, Miller J, Gu C, Evans W, Levine M: PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC).
  • : 7575 Background: In patients with NSCLC, preoperative staging tests including mediastinoscopy (M) are important in defining which patients are surgical candidates.
  • <sup>18</sup>FDG PET-CT is useful in identifying patients with mediastinal disease not evident by CT.
  • METHODS: In this analysis, we determined the accuracy of PET-CT in mediastinal staging compared to invasive surgical staging either by M alone or by M and T.
  • Of 21 patients with a positive PET-CT, 7 did not have tumor.
  • If PET-CT is negative in the mediastinum, the likelihood of occult metastatic disease in the mediastinum is very low and invasive staging may not be required depending on the clinical context.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kobayashi K, Tsuji A, Hata Y, Morita S, Horimi T: Retrospective study of the patients with unresectable gastric cancer (UNGC) who underwent a gastrectomy after receiving S-1 or S-1 combination chemotherapy (S-1+α). J Clin Oncol; 2009 May 20;27(15_suppl):e15668
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Today in Japan, S- 1+αincluding S+DTX, S+CPT-11 and S+PTX are the mainstay treatments for ARGC.
  • There are some case reports of pts with UNGC who were operated on due to the good anti-tumor effect of S-1+α, however, no consensus for performing a gastrectomy after chemotherapy has yet been reached.
  • Treatment regimens; S:13, S+DTX:3, and S+P:9.
  • RR was 56% (PR:14, SD:9, PD:2).
  • The features were DOWN (M/F=5/3/65 yrs/PR:8/L:6, D:0, N:4, P:3) and PAL (M/F=4/0/57 yrs/SD:4/L:1, D:3, N:1 P:1).
  • In addition, 8 pts experienced histological changes, in particular, one pt achieved Grade 3 (No viable tumor cells were found.).
  • CONCLUSIONS: The findings of this study suggest that the above described chemotherapeutic regimen combined with a second-look gastrectomy might therefore be a new potentially effective strategy for the treatment of UNGC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R: Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). J Clin Oncol; 2009 May 20;27(15_suppl):e19006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).
  • EGFR activating mutations correlate with adenocarcinoma histology, non-smoking history, female gender, and Asian ethnicity.
  • We will correlate these data with EGFR mutation and c-Met expression/mutations/amplifications for markers of NSCLC.
  • We then retrospectively collected demographic data (age, race, sex, and tobacco history), tumor histology, response rates, survival data and duration of response from AA pts treated with E as single agent.
  • Overall response rate of 13.6% (6-PR, 16-SD, 18-progessive disease, and 4 patients lost to follow up).
  • EGFR mutations and c-Met analysis will be provided by ASCO meeting in May 2009.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement